LONA LeonaBio, Inc.
XNAS 8.86 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
What changed
Recent filings, trades and moves- 52-Week Range
- $2.21 – $14.21
- YTD
- +35.27%
- Straddle Price
- $6.85
- P/C Vol Ratio (Apr 17 expiry)
- 0.00
- Market Cap
- $0.0B
- Open
- $2.71
- Day Range
- $2.37 – $2.93
- Volume
- 79,043
- Prev Close
- $2.65
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.74 |
| Cost of Equity (CAPM) | 8.87% (VRP-adj) |
| WACC | 8.09% |
| Volatility Risk Premium | -95.2pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -421.1% |
| Book / Price | 93.6% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $5.15 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $4.42 |
| Bollinger Width / SMA20 | 62.2% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $5.84 | 24% | median 2.3× · 3 peers |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $5.15 | 76% | stability 62% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |

- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 19
- List Date
- 2020-09-18
- CIK
- 0001620463
- Last Earnings
- Aug 14
- Headquarters
- Bothell, WA
- Homepage
- https://www.leonabio.com
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new …
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '26 | Avg |
|---|---|---|
| Jan | -27.63% | -27.63% |
| Feb | 21.08% | 21.08% |
| Mar | 79.72% | 79.72% |
| Apr | -9.18% | -9.18% |
| May | 8.16% | 8.16% |
| Jun | -1.08% | -1.08% |
| Jul | -15.85% | -15.85% |
| Aug | 6.02% | 6.02% |
| Sep | -52.96% | -52.96% |
| Oct | 12.79% | 12.79% |
| Nov | -43.97%* | -43.97% |
| Dec | -- | -- |
| Total | -59.42% | -59.42% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers: Strong technical momentum, low volatility, and positive options market signals.
Primary risks: News-driven surprises, potential mean reversion, and high-beta stocks influencing the sector.
Investment thesis: LONA has a strong technical foundation, with bullish momentum indicators and low volatility. The options market is pricing in a moderate move, which could be a buying opportunity.
Recent news sentiment impact: No recent news available, but this lack of news can also be seen as a positive factor, allowing the stock to focus on its technical signals.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish, Medium-term (1-3 months): Bullish, Long-term (3-12 months): Neutral
Support/Resistance Levels:
- SMA 20: $9.76 (support)
- Upper Bollinger Band: $11.23 (resistance)
Momentum Signals:
- RSI: 55.88 (neutral)
- MACD: Bullish (0.32 / -0.01 / 0.33)
- Stochastic %K/D: 52.54/52.37 (neutral)
- Williams %R: -38.28 (oversold)
Volume Analysis: Volume SMA 20: 39338.60, On-Balance Volume (OBV): 512954.83, Volume Rate of Change: -71.61%
News & Sentiment Analysis
Recent Headlines Summary: No recent news available.
Sentiment Assessment: Neutral (no recent news)
Catalyst Identification: None identified, but potential earnings releases or product launches could drive price movements in the future.
Market Narrative: The lack of recent news allows the stock to focus on its technical signals, which are currently pointing towards a bullish trend.
Risk & Volatility Assessment
Beta Interpretation: 0.06 (vs SPY), indicating low risk relative to the market.
Volatility Regime: Low volatility regime, with historical volatility metrics indicating a relatively calm market.
Options Market Signals:
- IV Rank: 0.0% (Low - shows if volatility is historically high/low)
- Current IV: 0.0%
- Expected Move: $6.85 (0 DTE), 7-DTE: $6.85
- Volume Flow: 50 calls vs 0 puts
- Open Interest: 146 calls vs 0 puts
- Put/Call Volume Ratio: 0.00 (Bullish sentiment)
- Put/Call OI Ratio: 0.00
Downside Protection: Support levels include SMA 20 at $9.76, and the lower Bollinger Band at $8.30.
Market Context & Positioning
Sector Performance: The sector is trading in line with market performance, with a slight bias towards growth stocks.
Institutional Activity: Institutional investors have been buying LONA shares in recent weeks, indicating accumulation.
Correlation Analysis: Correlation with the broader market (R-squared interpretation) suggests that LONA moves in tandem with the market.
Relative Valuation: LONA is trading near its historical mean, implying a relatively fair valuation.
Key Levels & Action Items
Critical Price Levels:
- SMA 20: $9.76 (support)
- Upper Bollinger Band: $11.23 (resistance)
Breakout/Breakdown Levels:
- Breakout above the upper Bollinger Band: Bullish signal
- Breakdown below the lower Bollinger Band: Bearish signal
Time-Sensitive Catalysts: Earnings releases or product launches could drive price movements in the future.
Risk Management: Consider stop-loss levels at SMA 20 and volume-based indicators, with position sizing considerations based on risk tolerance.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-03-26 | unknown | 70.76% | 7.33% | 0.10x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
LONA Options Activity & IV Rank
Volatility Metrics
Options Flow · Apr 17 expiry
ATM Options Pricing
Chain Summary
LONA Implied Volatility
Loading implied volatility…
The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much LONA actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 215
Period: 252 trading days
Moderate volatility - stock generally follows market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $298K | #3348 of 3716 | +2.4% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $203K | #2897 of 3151 | -26.4% | 13F | |
| Citadel Hedge fund Ken Griffin | $92K | #5822 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
LONA Institutional Ownership (13F)
Filings for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
LONA Insider Trading (Form 4)
Latest: 2026-10-28| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-28 | David J. Portman | 10%+ Owner | Buy (P) | +3,149,470 | $3149.47 | $9.92B | EDGAR |
| 2026-10-26 | PERCEPTIVE ADVISORS LLC | Director | Exer (M) | +776,648 | $0.00 | $777 | EDGAR |
| 2026-07-10 | Joseph Edelman | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2026-07-09 | Joseph Edelman | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2026-06-24 | Peter B. Silverman | Director | Grant (A) | +2,333 opt | — | EDGAR | |
| 2026-06-24 | Fred Callori | Director | Grant (A) | +2,333 opt | — | EDGAR | |
| 2026-06-24 | Michael A. Panzara | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2026-06-24 | Joseph Edelman | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2026-06-24 | Barbara Kosacz | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2026-06-24 | Natalie C. Holles | Director | Grant (A) | +2,333 opt | — | EDGAR | |
| 2026-06-24 | Grant Pickering | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2026-06-24 | Kelly A Romano | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2026-06-24 | James A Johnson | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2026-05-07 | Natalie C. Holles | Director | Grant (A) | +56,000 opt | — | EDGAR | |
| 2026-05-07 | Peter B. Silverman | Director | Grant (A) | +56,000 opt | — | EDGAR |
LONA Insider Holdings
7 insiders · @ $2.40| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | David J. Portman | 10%+ Owner | 3,149,470 | $7.56M | $9.92B | 1 | 2026-10-28 |
| 2 | PERCEPTIVE ADVISORS LLC | Director | 776,648 | $1.86M | $0 | 1 | 2026-10-26 |
| 3 | Mark James Litton | PRESIDENT and CEO | 59,894 | $143.7K | -$27.7K | 2 | 2026-04-13 |
| 4 | Kevin Church | CHIEF SCIENTIFIC OFFICER | 25,178 | $60.4K | -$7.3K | 2 | 2026-04-13 |
| 5 | Mark Worthington | GENERAL COUNSEL and CCO | 18,376 | $44.1K | -$7.1K | 2 | 2026-04-13 |
| 6 | Martin Javier San | CHIEF MEDICAL OFFICER | 15,887 | $38.1K | -$9.2K | 2 | 2026-04-13 |
| 7 | Robert Renninger | CHIEF FINANCIAL OFFICER | 15,851 | $38.0K | -$4.9K | 2 | 2026-04-13 |
LONA Board & Officers
As of SEC filings through Oct 28, 2026Directors 14
- James A Johnson · since Sep 17, 2020
- John M Fluke Jr · since Sep 17, 2020
- Joseph Edelman · since Sep 17, 2020
- Kelly A Romano · since Dec 11, 2020
- Perceptive Advisors LLC (entity) · listed since Jan 2021
- Perceptive Life Sciences Master Fund Ltd (entity) · listed since Jan 2021
- Barbara Kosacz · since Mar 4, 2021
- Grant Pickering · since Jan 27, 2022
- Mark James Litton · listed since Jan 2022
- Michael A. Panzara · since Mar 18, 2022
- Perceptive Xontogeny Venture Fund II, LP (entity) · on file since Dec 2025
- Fred Callori · since May 5, 2026
- Natalie C. Holles · since May 5, 2026
- Peter B. Silverman · since May 5, 2026
Officers 5
- Mark James Litton · President and CEO · listed since Sep 2024
- Robert Renninger · Chief Financial Officer · listed since Dec 2025
- Kevin Church · Chief Scientific Officer · listed since Mar 2023
- Martin Javier San · Chief Medical Officer · since Apr 15, 2024
- Mark Worthington · General Counsel and CCO · listed since Oct 2024
10% owners 5
- David J. Portman · since Aug 24, 2026
- Joseph Edelman · listed since Jul 2026
- Perceptive Advisors LLC (entity) · since Sep 17, 2020
- Perceptive Life Sciences Master Fund Ltd (entity) · since Sep 17, 2020
- Perceptive Xontogeny Venture Fund II, LP (entity) · on file since Dec 2025
Changes in the last 10 years (54)
| Aug 24, 2026 | David J. Portman became a 10% owner |
| Jul 9, 2026 | Joseph Edelman first listed as a 10% owner in an SEC filing |
| May 5, 2026 | Peter B. Silverman became a director |
| May 5, 2026 | Natalie C. Holles became a director |
| May 5, 2026 | Fred Callori became a director |
| Apr 13, 2026 | Joseph Edelman no longer listed as a 10% owner in SEC filings |
| Dec 29, 2025 | Robert Renninger listed as Chief Financial Officer (previously SVP, Finance and Accounting) in SEC filings |
| Dec 23, 2025 | Perceptive Xontogeny Venture Fund II, LP first on file as a director |
| Dec 23, 2025 | Perceptive Xontogeny Venture Fund II, LP first on file as a 10% owner |
| Dec 23, 2025 | Joseph Edelman first listed as a 10% owner in an SEC filing |
| Mar 4, 2025 | Robert Renninger listed as SVP, Finance and Accounting (previously VP of Finance) in SEC filings |
| Oct 3, 2024 | Mark Worthington listed as General Counsel and CCO (previously General Counsel) in SEC filings |
| Oct 1, 2024 | Robert Renninger became VP of Finance |
| Sep 5, 2024 | Mark James Litton listed as President and CEO (previously Chief Executive Officer) in SEC filings |
| May 24, 2024 | Joseph Edelman no longer listed as a 10% owner in SEC filings |
| Apr 15, 2024 | Martin Javier San became Chief Medical Officer |
| Feb 16, 2024 | Rachel Lenington listed as COO and Cdo (previously Chief Operating Officer) in SEC filings |
| Feb 16, 2024 | Andrew Gengos listed as CFO and Chief Business Officer (previously See Below) in SEC filings |
| Jan 4, 2024 | The company announced the departure of Hans Moebius as Chief Medical Officer in an SEC filing |
| May 22, 2023 | The company announced the departure of Glenna Mileson as Chief Financial Officer in an SEC filing |
| May 18, 2023 | Andrew Gengos became See Below |
| Mar 27, 2023 | Kevin Church listed as Chief Scientific Officer (previously Executive VP, Research) in SEC filings |
| Jul 1, 2022 | Joseph Edelman first listed as a 10% owner in an SEC filing |
| Mar 18, 2022 | Michael A. Panzara became a director |
| Jan 31, 2022 | Mark James Litton listed as Chief Executive Officer (previously Chief Operating Officer) in SEC filings |
| Jan 31, 2022 | Mark James Litton first listed as a director in an SEC filing |
| Jan 27, 2022 | Grant Pickering became a director |
| Jan 20, 2022 | Kevin Church listed as Executive VP, Research (previously Vice President of Discovery) in SEC filings |
| Nov 5, 2021 | Rachel Lenington listed as Chief Operating Officer (previously Chief Technology Officer) in SEC filings |
| Jun 14, 2021 | Rachel Lenington became Chief Technology Officer |
| Jun 1, 2021 | Mark Worthington became General Counsel |
| Jun 1, 2021 | Joseph Edelman no longer listed as a 10% owner in SEC filings |
| Mar 4, 2021 | Barbara Kosacz became a director |
| Jan 27, 2021 | Perceptive Life Sciences Master Fund Ltd first listed as a director in an SEC filing |
| Jan 27, 2021 | Perceptive Advisors LLC first listed as a director in an SEC filing |
| Dec 11, 2020 | Kelly A Romano became a director |
| Sep 22, 2020 | Rtw Investments, LP reported in an SEC filing no longer being a 10% owner |
| Sep 22, 2020 | Roderick Wong reported in an SEC filing no longer being a 10% owner |
| Sep 17, 2020 | Tadataka Yamada became a director |
| Sep 17, 2020 | Rtw Investments, LP became a 10% owner |
| Sep 17, 2020 | Roderick Wong became a 10% owner |
| Sep 17, 2020 | Perceptive Life Sciences Master Fund Ltd became a 10% owner |
| Sep 17, 2020 | Perceptive Advisors LLC became a 10% owner |
| Sep 17, 2020 | Mark James Litton became Chief Operating Officer |
| Sep 17, 2020 | Leen Kawas became a director |
| Sep 17, 2020 | Leen Kawas became a 10% owner |
| Sep 17, 2020 | Leen Kawas became President & CEO |
| Sep 17, 2020 | Kevin Church became Vice President of Discovery |
| Sep 17, 2020 | Joseph Edelman became a director |
| Sep 17, 2020 | Joseph Edelman became a 10% owner |
| Sep 17, 2020 | John M Fluke Jr became a director |
| Sep 17, 2020 | James A Johnson became a director |
| Sep 17, 2020 | Hans Moebius became Chief Medical Officer |
| Sep 17, 2020 | Glenna Mileson became Chief Financial Officer |
- Prev
- 1
Not reported recently (4)
- Rachel Lenington · Last reported as COO and Cdo in an SEC filing dated Sep 5, 2024
- Andrew Gengos · Last reported as CFO and Chief Business Officer in an SEC filing dated Sep 5, 2024
- Tadataka Yamada · Last reported as a director in an SEC filing dated Jun 1, 2021
- Leen Kawas · Last reported as a director in an SEC filing dated Feb 22, 2021
LONA Proposed Insider Sales (Form 144)
Latest: 2026-03-04What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Mark James Litton | Officer, Director | 5,156 | $27.7K | 2026-03-04 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-07-01 | Mark James Litton | Officer, Director | 25,123 | $7.4K | 2025-07-01 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-07-01 | Javier San Martin | Officer | 10,842 | $3.2K | 2025-07-01 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-07-01 | Kevin Church | Officer | 8,526 | $2.5K | 2025-07-01 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-07-01 | Mark Worthington | Officer | 8,526 | $2.5K | 2025-07-01 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-01-02 | Javier San Martin | Officer | 10,826 | $6.1K | 2025-01-02 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-01-02 | Mark James Litton | Officer, Director | 25,107 | $14.1K | 2025-01-02 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-01-02 | Mark Worthington | Officer | 8,510 | $4.8K | 2025-01-02 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-01-02 | Kevin Church | Officer | 8,510 | $4.8K | 2025-01-02 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-09-05 | Mark James Litton | Officer, Director | 5,032 | $1 | 2024-09-05 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| Filing Date | Accession | Link |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | SURI Simplify Propel Opportunities ETF | Nport | 1.78% | $1.4M | — | 2026-06-30 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $713,400 | — | 2026-10-31 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $407,007 | — | 2026-10-31 |
| 4 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.00% | $54,369 | $1.2B | 2026-11-17 |
| 5 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.00% | $10,416 | — | 2026-11-17 |
| 6 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $10,033 | — | 2026-11-17 |
| 7 | DFSU Dimensional US Sustainability Core 1 ETF | Dimensional | 0.00% | $911 | $2.3B | 2026-11-17 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Quarterly figures (3 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $0.00 | $-21.16M | $-0.89 | $-18.89M |
| Q2 '26 | 2026-06-30 | $0.00 | $-19.01M | $-0.80 | $-16.96M |
| Q1 '26 | 2026-03-31 | $0.00 | $-32.96M | $-1.73 | $-20.90M |
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
LONA vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| CORT Corcept Therapeutics Inc. | $7.3B | 51.3 | +30.0% | +70.6% | 100 |
| CLDX Celldex Therapeutics, Inc | $2.2B | — | −93.9% | +3.3% | 4 |
| DCTH Delcath Systems Inc | $685M | 119.8 | +38.1% | +92.6% | 23 |
| QUIT Achieve Life Sciences, Inc. | $651M | — | — | — | — |
| PHAT Phathom Pharmaceuticals, Inc. Common Sto | $431M | — | +86.8% | −67.7% | 30 |
| KYTX Kyverna Therapeutics, Inc. Common Stock | $283M | — | — | −50.2% | 15 |
| ABEO Abeona Therapeutics Inc. Common Stock | $168M | — | +9652.8% | −53.2% | 12 |
| MIST Milestone Pharmaceuticals Inc. Common Sh | $57M | — | — | −80.6% | — |
| LONA LeonaBio, Inc. Common Stock | $35M | — | — | −63.4% | — |
| Peer median | $541M | 85.5 | +38.1% | −50.2% | 19 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.